Akoya Biosciences And NeraCare Sign Exclusive Global License Agreement To Develop And Commercialize Immunoprint Test For Early-Stage Melanoma Treatment Decisions, Leveraging Akoya's PhenoImager HT Platform To Address High-Risk Relapse Patients With...
Akoya Biosciences And NeraCare Sign Exclusive Global License Agreement To Develop And Commercialize Immunoprint Test For Early-Stage Melanoma Treatment Decisions, Leveraging Akoya's PhenoImager HT Platform To Address High-Risk Relapse Patients With...
Akoya Biosciences与NeraCare签署独家全球许可协议，以开发和商业化用于早期黑色素瘤治疗决策的免疫打印测试，利用Akoya的PhenoImager Ht平台来解决高风险股票复发患者的...
Akoya Biosciences And NeraCare Sign Exclusive Global License Agreement To Develop And Commercialize Immunoprint Test For Early-Stage Melanoma Treatment Decisions, Leveraging Akoya's PhenoImager HT Platform To Address High-Risk Relapse Patients With Potential Therapeutic Benefits
Akoya Biosciences和NeraCare签署独家全球许可协议，利用Akoya的PhenoImager Ht平台为具有潜在治疗益处的高风险复发患者开发和商业化用于早期黑色素瘤治疗决策的免疫打印测试
热门讨论
FOMC维持利率但不确定性高企：美股后市走向如何？
🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？
Moo Live
03/20 02:25
联邦公开市场委员会新闻发布会，2025年3月19日